Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098002 | 0.82 | MEN1 (0.46) | NOS2L3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL27640670 | 0.81 | NOS3 (0.50) | NOS3NOS1NOS2ALDH1A1NPSR1 | |
| SCHEMBL4659391 | 0.81 | MAPT (0.48) | NOS3NOS1NOS2L3MBTL1SMN1; SMN2 | |
| SCHEMBL4993348 | 0.80 | PDGFRB (0.56) | NOS3NOS1NOS2L3MBTL1SMN1; SMN2 | |
| SCHEMBL5101717 | 0.79 | MAPT (0.48) | L3MBTL1ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL29848581 | 0.77 | TSHR (0.47) | NOS3NOS1NOS2L3MBTL1SMN1; SMN2 | |
| SCHEMBL21061659 | 0.77 | TSHR (0.47) | NOS3NOS1NOS2L3MBTL1SMN1; SMN2 | |
| SCHEMBL15234195 | 0.76 | MAPT (0.50) | NOS3NOS1NOS2L3MBTL1SMN1; SMN2 | |
| SCHEMBL1663911 | 0.75 | NOS3 (0.63) | NOS3NOS1NOS2L3MBTL1ALDH1A1 | |
| SCHEMBL30436280 | 0.74 | PKM (0.44) | NOS3NOS1NOS2L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1597260-B1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-7119088-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060194794-A1 | Triazole compounds useful in therapy | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| EP-1597260-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194794-A1 | Triazole compounds useful in therapy | CYP3A43, CYP3A5, CYP3A7 | NOS3 1203/4885NOS1 2717/4885NOS2 2272/4885 |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | CNR1, NR1H2, OXER1 | NOS3 1853/4885NOS1 2229/4885NOS2 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.